A long non-coding RNA signature in glioblastoma multiforme predicts survival

Neurobiology of Disease

Volumn 58, Issue , 2013, Pages 123-131

  Zhang, Xiao Qin ^a   Sun, Stella ^a   Lam, Kwok Fai ^b   Kiang, Karrie Mei Yee ^a   Pu, Jenny Kan Suen ^a   Ho, Amy Shuk Wai ^a   Lui, Wai Man ^a   Fung, Ching Fai ^a   Wong, Thian Sze ^a   Leung, Gilberto Ka Kit ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Biomarkers; Glioblastoma; LncRNAs; MGMT; Prognosis

Indexed keywords

LONG UNTRANSLATED RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GLIOBLASTOMA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION;

BIOMARKERS; GLIOBLASTOMA; LNCRNAS; MGMT; PROGNOSIS;

AGE FACTORS; BRAIN NEOPLASMS; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROARRAY ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RNA, LONG NONCODING; TIME FACTORS;

EID: 84879424212     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.05.011     Document Type: Article

References (58)

1. Anon Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
2. Adamson C., et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert. Opin. Investig. Drugs 2009, 18:1061-1083.
3. Alizadeh A.A., et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011, 118:1350-1358.
4. Cesana M., et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011, 147:358-369.
5. Cui Z., et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol. Oncol. 2013, (in press).
6. de Kok J.B., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002, 62:2695-2698.
7. Ducray F., et al. Diagnostic and prognostic markers in gliomas. Curr. Opin. Oncol. 2009, 21:537-542.
8. Ellis B.C., et al. CRNDE: a long non-coding RNA involved in cancer, neurobiology, and development. Front. Genet. 2012, 3:270.
9. Felsberg J., et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin. Cancer Res. 2009, 15:6683-6693.
10. Gibb E.A., et al. The functional role of long non-coding RNA in human carcinomas. Mol. Cancer 2011, 10:38.
11. Gravendeel L.A., et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009, 69:9065-9072.
12. Gupta R.A., et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464:1071-1076.
13. Han L., et al. LncRNA profile of glioblastoma reveals the potential role of lncRNAs in contributing to glioblastoma pathogenesis. Int. J. Oncol. 2012, 40:2004-2012.
14. Hegi M.E., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
15. Irizarry R.A., et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31:e15.
16. Ishii N., et al. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J. Hum. Genet. 2006, 51:1087-1099.
17. Jansen M., et al. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010, 9:717-726.
18. Ji P., et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003, 22:8031-8041.
19. Johnson R. Long non-coding RNAs in Huntington's disease neurodegeneration. Neurobiol. Dis. 2012, 46:245-254.
20. Khaitan D., et al. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res. 2011, 71:3852-3862.
21. Lin B., et al. PART-1: a novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12. Cancer Res. 2000, 60:858-863.
22. Lipovich L., et al. MacroRNA underdogs in a microRNA world: evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA. Biochim. Biophys. Acta-Gene Regul. Mech. 2010, 1799:597-615.
23. Liu C., et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011, 146:209-221.
24. Lossos I.S., et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 2004, 350:1828-1837.
25. Mercer T.R., et al. Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 2009, 10:155-159.
26. Mercer T.R., et al. Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation. BMC Neurosci. 2010, 11:14.
27. Michelhaugh S.K., et al. Mining Affymetrix microarray data for long non-coding RNAs: altered expression in the nucleus accumbens of heroin abusers. J. Neurochem. 2011, 116:459-466.
28. Mitra S.A., et al. A central role for long non-coding RNA in cancer. Front. Genet. 2012, 3:17.
29. Mourtada-Maarabouni M., et al. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009, 28:195-208.
30. Murat A., et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol. 2008, 26:3015-3024.
31. Ning Y., et al. Identification of a novel paternally expressed transcript adjacent to snRPN in the Prader-Willi syndrome critical region. Genome Res. 1996, 6:742-746.
32. Noushmehr H., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
33. Pang J.C., et al. KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathol. 2010, 20:1021-1032.
34. Prensner J.R., Chinnaiyan A.M. The emergence of lncRNAs in cancer biology. Cancer Discov. 2011, 1:391-407.
35. Qi P., Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod. Pathol. 2013, 26:155-165.
36. Rivera A.L., Pelloski C.E. Diagnostic and prognostic molecular markers in common adult gliomas. Expert. Rev. Mol. Diagn. 2010, 10:637-649.
37. Salmena L., et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 2011, 146:353-358.
38. Sheik Mohamed J., et al. Conserved long noncoding RNAs transcriptionally regulated by Oct4 and Nanog modulate pluripotency in mouse embryonic stem cells. RNA 2010, 16:324-337.
39. Simon R., et al. Analysis of gene expression data using BRB-ArrayTools. Cancer Informat. 2007, 3:11-17.
40. Smith J.S., et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 2000, 18:636-645.
41. Srinivasan S., et al. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011, 6:e17438.
42. Stupp R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
43. Stupp R., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
44. Tabatabai G., et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. 2010, 120:585-592.
45. Turcan S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483. (479-U137).
46. Verhaak R.G., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
47. Wang J., et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010, 38:5366-5383.
48. Wang P., et al. Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J. Cell. Biochem. 2012, 113:1868-1874.
49. Weller M. Temozolomide and MGMT forever?. Neuro Oncol. 2010, 12:219-220.
50. Weller M., et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat. Rev. Neurol. 2010, 6:39-51.
51. Weller M., et al. Individualized targeted therapy for glioblastoma: fact or fiction?. Cancer J. 2012, 18:40-44.
52. Wick W., et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012, 13:707-715.
53. Williams G.T., et al. A critical role for non-coding RNA GAS5 in growth arrest and rapamycin inhibition in human T-lymphocytes. Biochem. Soc. Trans. 2011, 39:482-486.
54. Woo H.G., et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin. Cancer Res. 2008, 14:2056-2064.
55. Yang F., et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 2011, 54:1679-1689.
56. Yang J.H., et al. ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res. 2013, 41:D177-D187.
57. Yu S.L., et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13:48-57.
58. Zhang X., et al. Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol. Dis. 2012, 48:1-8.